1 Introduction to Research & Analysis Reports
1.1 Primary Immunodeficiency Therapeutic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Primary Immunodeficiency Therapeutic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Primary Immunodeficiency Therapeutic Overall Market Size
2.1 Global Primary Immunodeficiency Therapeutic Market Size: 2022 VS 2029
2.2 Global Primary Immunodeficiency Therapeutic Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Primary Immunodeficiency Therapeutic Players in Global Market
3.2 Top Global Primary Immunodeficiency Therapeutic Companies Ranked by Revenue
3.3 Global Primary Immunodeficiency Therapeutic Revenue by Companies
3.4 Top 3 and Top 5 Primary Immunodeficiency Therapeutic Companies in Global Market, by Revenue in 2022
3.5 Global Companies Primary Immunodeficiency Therapeutic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Players in Global Market
3.6.1 List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies
3.6.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Primary Immunodeficiency Therapeutic Market Size Markets, 2022 & 2029
4.1.2 Immunoglobulin Replacement Therapy
4.1.3 Stem Cell or Bone Marrow Transplantation
4.1.4 Antibiotic Therapy
4.1.5 Gene Therapy
4.1.6 Others
4.2 By Type – Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
4.2.1 By Type – Global Primary Immunodeficiency Therapeutic Revenue, 2018-2023
4.2.2 By Type – Global Primary Immunodeficiency Therapeutic Revenue, 2024-2029
4.2.3 By Type – Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Primary Immunodeficiency Therapeutic Market Size, 2022 & 2029
5.1.2 Antibody Deficiency
5.1.3 Cellular Immunodeficiency
5.1.4 Innate Immune Disorders
5.1.5 Others
5.2 By Application – Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
5.2.1 By Application – Global Primary Immunodeficiency Therapeutic Revenue, 2018-2023
5.2.2 By Application – Global Primary Immunodeficiency Therapeutic Revenue, 2024-2029
5.2.3 By Application – Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Primary Immunodeficiency Therapeutic Market Size, 2022 & 2029
6.2 By Region – Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
6.2.1 By Region – Global Primary Immunodeficiency Therapeutic Revenue, 2018-2023
6.2.2 By Region – Global Primary Immunodeficiency Therapeutic Revenue, 2024-2029
6.2.3 By Region – Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.3.2 US Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.3.3 Canada Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.3.4 Mexico Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.4.2 Germany Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.3 France Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.4 U.K. Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.5 Italy Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.6 Russia Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.7 Nordic Countries Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.8 Benelux Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.5.2 China Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.3 Japan Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.4 South Korea Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.5 Southeast Asia Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.6 India Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.6.2 Brazil Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.6.3 Argentina Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.7.2 Turkey Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7.3 Israel Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7.4 Saudi Arabia Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7.5 UAE Primary Immunodeficiency Therapeutic Market Size, 2018-2029
7 Primary Immunodeficiency Therapeutic Companies Profiles
7.1 Baxter International
7.1.1 Baxter International Company Summary
7.1.2 Baxter International Business Overview
7.1.3 Baxter International Primary Immunodeficiency Therapeutic Major Product Offerings
7.1.4 Baxter International Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.1.5 Baxter International Key News & Latest Developments
7.2 Takeda Pharmaceutical
7.2.1 Takeda Pharmaceutical Company Summary
7.2.2 Takeda Pharmaceutical Business Overview
7.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Major Product Offerings
7.2.4 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.2.5 Takeda Pharmaceutical Key News & Latest Developments
7.3 CSL Limited
7.3.1 CSL Limited Company Summary
7.3.2 CSL Limited Business Overview
7.3.3 CSL Limited Primary Immunodeficiency Therapeutic Major Product Offerings
7.3.4 CSL Limited Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.3.5 CSL Limited Key News & Latest Developments
7.4 Octapharma
7.4.1 Octapharma Company Summary
7.4.2 Octapharma Business Overview
7.4.3 Octapharma Primary Immunodeficiency Therapeutic Major Product Offerings
7.4.4 Octapharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.4.5 Octapharma Key News & Latest Developments
7.5 Kedrion Biopharma
7.5.1 Kedrion Biopharma Company Summary
7.5.2 Kedrion Biopharma Business Overview
7.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Major Product Offerings
7.5.4 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.5.5 Kedrion Biopharma Key News & Latest Developments
7.6 Bio Products Laboratory
7.6.1 Bio Products Laboratory Company Summary
7.6.2 Bio Products Laboratory Business Overview
7.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Major Product Offerings
7.6.4 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.6.5 Bio Products Laboratory Key News & Latest Developments
7.7 LFB group
7.7.1 LFB group Company Summary
7.7.2 LFB group Business Overview
7.7.3 LFB group Primary Immunodeficiency Therapeutic Major Product Offerings
7.7.4 LFB group Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.7.5 LFB group Key News & Latest Developments
7.8 Grifols
7.8.1 Grifols Company Summary
7.8.2 Grifols Business Overview
7.8.3 Grifols Primary Immunodeficiency Therapeutic Major Product Offerings
7.8.4 Grifols Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.8.5 Grifols Key News & Latest Developments
7.9 Lupin Pharmaceuticals
7.9.1 Lupin Pharmaceuticals Company Summary
7.9.2 Lupin Pharmaceuticals Business Overview
7.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Major Product Offerings
7.9.4 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.9.5 Lupin Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Primary Immunodeficiency Therapeutic Market Opportunities & Trends in Global Market
Table 2. Primary Immunodeficiency Therapeutic Market Drivers in Global Market
Table 3. Primary Immunodeficiency Therapeutic Market Restraints in Global Market
Table 4. Key Players of Primary Immunodeficiency Therapeutic in Global Market
Table 5. Top Primary Immunodeficiency Therapeutic Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Primary Immunodeficiency Therapeutic Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Primary Immunodeficiency Therapeutic Revenue Share by Companies, 2018-2023
Table 8. Global Companies Primary Immunodeficiency Therapeutic Product Type
Table 9. List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 30. Baxter International Company Summary
Table 31. Baxter International Primary Immunodeficiency Therapeutic Product Offerings
Table 32. Baxter International Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 33. Baxter International Key News & Latest Developments
Table 34. Takeda Pharmaceutical Company Summary
Table 35. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product Offerings
Table 36. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 37. Takeda Pharmaceutical Key News & Latest Developments
Table 38. CSL Limited Company Summary
Table 39. CSL Limited Primary Immunodeficiency Therapeutic Product Offerings
Table 40. CSL Limited Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 41. CSL Limited Key News & Latest Developments
Table 42. Octapharma Company Summary
Table 43. Octapharma Primary Immunodeficiency Therapeutic Product Offerings
Table 44. Octapharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 45. Octapharma Key News & Latest Developments
Table 46. Kedrion Biopharma Company Summary
Table 47. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product Offerings
Table 48. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 49. Kedrion Biopharma Key News & Latest Developments
Table 50. Bio Products Laboratory Company Summary
Table 51. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product Offerings
Table 52. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 53. Bio Products Laboratory Key News & Latest Developments
Table 54. LFB group Company Summary
Table 55. LFB group Primary Immunodeficiency Therapeutic Product Offerings
Table 56. LFB group Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 57. LFB group Key News & Latest Developments
Table 58. Grifols Company Summary
Table 59. Grifols Primary Immunodeficiency Therapeutic Product Offerings
Table 60. Grifols Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 61. Grifols Key News & Latest Developments
Table 62. Lupin Pharmaceuticals Company Summary
Table 63. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product Offerings
Table 64. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 65. Lupin Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Primary Immunodeficiency Therapeutic Segment by Type in 2022
Figure 2. Primary Immunodeficiency Therapeutic Segment by Application in 2022
Figure 3. Global Primary Immunodeficiency Therapeutic Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Primary Immunodeficiency Therapeutic Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Primary Immunodeficiency Therapeutic Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2022
Figure 8. By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 9. By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 10. By Type - Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 12. By Application - Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 14. By Region - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 15. By Country - North America Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 16. US Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 20. Germany Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 21. France Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 28. China Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 32. India Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 34. Brazil Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 37. Turkey Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 41. Baxter International Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. CSL Limited Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Octapharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. LFB group Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Grifols Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

※参考情報 原発性免疫不全治療薬は、免疫系に関連する先天的な異常に起因する疾病の治療に用いられる薬剤を指します。原発性免疫不全症（PID）は、体の免疫システムが正常に機能しないことによって引き起こされ、主に感染症に対する感受性が高まることが特徴です。これらの疾患は、遺伝子的な要因から生じることが多く、患者はさまざまな感染症に繰り返しかかることが一般的です。 原発性免疫不全症の治療には、主に感染症の予防と管理、免疫系の機能改善を目的とした治療法が含まれます。治療薬は、主に免疫グロブリン製剤や酵素補充療法などのカテゴリーに分かれます。これらの薬剤は、患者の免疫機能を補完または強化し、感染症のリスクを低減させる役割を果たします。 免疫グロブリン製剤は、一般的にIgG（免疫グロブリンG）を含む血漿由来の製剤であり、感染症に対する抗体を提供します。これにより、免疫不全患者が感染症に対処しやすくなるため、感染症の頻度を減少させることが期待されます。慢性的な感染を有する患者では、定期的な投与が推奨されます。 酵素補充療法は、遺伝的な疾患によって不足する酵素を補充する治療法です。この治療法は、特定の原発性免疫不全症に対して効果を示します。例如、糖質の代謝に関連する酵素が欠損している場合、これを補充することで正常な免疫機能を促進します。 治療の選択は患者の状態や病歴によって大きく異なります。診断の際には、遺伝子検査や免疫学的検査が行われ、特定の免疫不全のタイプが明確化されます。これにより、よりターゲットを絞った治療法の選択が可能となり、効果的な管理が行えるようになります。 最近の技術進歩により、遺伝子治療や細胞治療が原発性免疫不全症の新たな治療アプローチとして注目されています。これらの技術は、遺伝的な疾患の根本的な原因に対処するものであり、免疫系の細胞を再プログラムしたり、遺伝子修復を行ったりします。これにより、長期的には従来の治療法に代わる可能性が期待されています。 他にも、モノクローナル抗体製剤が原発性免疫不全症の補助療法として用いられるケースがあります。これにより、特定の病原体に対する特異的な免疫応答を強化することが試みられています。 さらには、生活習慣の改善や栄養管理も原発性免疫不全症の管理において重要な要素です。これには、適切な食事、身体活動、ストレス管理などが含まれ、全体的な健康状態を改善し、感染症のリスクを低減させることが可能です。 総じて、原発性免疫不全治療薬は、様々な免疫系の異常に対処するために開発されており、治療方法の選択肢は増加しています。今後の研究により、新たな治療法の発見や改良が期待されており、原発性免疫不全症患者に対する治療成績の向上が見込まれています。これにより、患者の生活の質を向上させ、より良い健康状態を維持するためのサポートが可能となるでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer